News & Insights Search

The US Food and Drug Administration (FDA) has warned an oncology drug company for repeatedly overstating the efficacy of its drug in advertisements while failing to adequately disclose the associated risks. The agency also issued several warning letters to companies for violations of current good manufacturing practices (CGMP) and for marketing products for non-approved indications.

Welcome to another installment of This Week at FDA, your weekly source for updates—big and small—on FDA, drug, and medical device regulation and what we're reading from around the web. This week, top FDA officials announced that the agency would require only a single pivotal trial for most drugs, the agency reversed course and said it would review Moderna's mRNA influenza vaccine, and FDA Commissioner Marty Makary said that most drugs should be available over-the-counter (OTC).

Pharmaceutical industry groups, drugmakers, and other industry stakeholders are pressuring the US Food and Drug Administration (FDA) to finalize its proposed rule to update the format of the National Drug Code (NDC) by the end of March 2026.

Stakeholders want the US Food and Drug Administration (FDA) to clarify and streamline regulatory requirements for sponsors of nonprescription over-the-counter (OTC) drugs. They also cautioned that the agency should avoid measures that could harm the generic drug industry, which could ultimately raise drug prices.

The US Food and Drug Administration (FDA) has finalized a guidance on how to conduct formal dispute resolutions (FDR) and administrative hearings to resolve scientific and/or medical disputes with sponsors of over-the-counter (OTC) drugs. The agency updated the draft version of the guidance to clarify limitations of the FDR process and ensure that requesters don't use multiple venues to address the same order.

Welcome to Regulatory Reconnaissance, your regulatory news and intelligence briefing.

The US Food and Drug Administration (FDA) recently posted four warning letters to pharmaceutical manufacturers in the US, Canada, and China for violations of current good manufacturing practices (CGMPs) and for marketing unapproved drug products.

The US Food and Drug Administration (FDA) on Tuesday reprimanded a US manufacturer and contract testing lab, BRS Analytical Services, for producing eye drops under unsanitary conditions, and an Australian company, Melcare, for making unapproved drug claims regarding their eye drops.